Epilepsy is a group of neurological disorders characterized by 30 the occurrence of unprovoked seizures (Fisher et al., 2014) .
31
Epilepsy is a major public health problem that affects more (Kwan and Brodie, 2000) , thus there is a need for new thera-40 peutic approaches that could potentially treat patients with 41 drug-resistant epilepsies (Jutila et al., 2002) . Astrocytes are a critical component of the tripartite 57 synapse, where they are involved in the active control of 58 neuronal activity and synaptic neurotransmission (Araque 59 et al., 1999) . Astrocytes are also involved in ion homeosta-60 sis, regulation of extracellular space volume and clearance 61 of neurotransmitters (Araque et al., 2014) . Astrocytic gluta- (Hubbard et al., 2016) .
77
In this study, we aimed to further our understanding of 
Kainic-acid induced status epilepticus

96
Intrahippocampal kainic acid (IHKA) injections were used to 97 induce epileptogenesis as previously described (Lee et al., 98 2012; Hubbard et al., 2016) . Mice were anesthetized with 99 a solution of ketamine (80 mg/kg)/xylazine (10 mg/kg) and 100 positioned in a stereotaxic frame. The skull was exposed, 101 bregma was located, and a craniotomy was performed 102 1.8 mm posterior and 1.6 mm lateral to bregma. Mice were 103 injected with either 64 nL of 0.9% saline or 20 mM kainic 104 acid (Tocris) using a microinjector (Nanoject II, Drummond 105 Scientific) into the CA1 region of the dorsal hippocampus 106 (lowered to 1.9 mm dorsoventral). Following injections, 107 mice experienced status epilepticus, defined by Racine 108 scale stage 3-5 seizures (Racine, 1972) for at least 3 h. 109 The presence of epileptiform activity and the development 110 of spontaneous seizures has previously been confirmed 111 by chronic video-EEG recordings to occur in 100% of ani-112 mals after IHKA injections (Lee et al., 2012) . We monitored 113 mice for 5 h following IHKA injection using video recording 114 to verify the presence of Racine stage 3-5 seizures. All ani-115 mals included in this study experienced continuous status 116 epilepticus (SE), characterized by forelimb and hindlimb clo-117 nus, rearing, jumping, and falling (Racine, 1972) . Animals 118 that died due to SE were excluded from the study. Mice 119 were euthanized at 1, 3, 7, and 30 days (n = 9 for each time (Fig. 1A) was carefully modified from 
237 was used for samples that had normal distribution and equal 238 variance. If either normal distribution and/or equal variance 239 assumptions were not satisfied, a Kruskal-Wallis (H) non-240 parametric test was used with Dunn's multiple comparisons 241 tests. All data points were depicted in figures for data ana-242 lyzed using non-parametric tests. All error bars are pre-243 sented as the mean ± standard error of the mean (SEM). 244 Difference from saline control was considered statistically 245 significant by a P-value < 0.05, < 0.01, < 0.001 or < 0.0001 246 and was denoted with one, two, three or four asterisks (*), 247 respectively. Difference between treatments was quantified 248 for Western blot analysis and was considered statistically 249 significant by a P-value of < 0.05 or < 0.01 and was denoted 250 with one or two asterisks (*), respectively. Saline controls 251 were grouped after initial statistical analysis performed 252 using an unpaired t-test showed no significant differences 253 between 1-and 7-day saline-injected controls (P > .05).
254
RESULTS
255
We found a significant increase in GLT-1 immunoreactivity at 1 256 and 3 days post-IHKA in both hippocampi and a significant 257 downregulation at 7 days post-IHKA in the ipsilateral hippo-258 campus. GLT-1 synaptosomal protein levels were significantly 259 decreased 7 days post-IHKA in the ipsilateral hippocampus. 260 GLAST immunoreactivity was significantly increased at 1 day 261 and 3 days post-IHKA in the ipsilateral hippocampus. GLAST 262 synaptosomal protein levels were not significantly different 263 from saline controls but there was a significant difference in 264 ipsilateral GLAST synaptosomal levels between 7 days and 265 30 days post-IHKA in the ipsilateral hippocampus. These 266 results indicate a significant change in glutamate transporter 267 expression and localization during epileptogenesis.
268 Glutamate transporter-1 (GLT-1) expression in the 269 dorsal hippocampus 270 Hippocampal GLT-1 and GFAP immunoreactivity were 271 assessed at 1, 3, 7 and 30 days post-intrahippocampal kai-272 nic acid (IHKA) induced status epilepticus (SE) and for 273 saline-injected animals (controls) for hippocampi both ipsi-274 lateral (Fig. 2, Fig. 3 ) and contralateral (Fig. 4, Fig. 5 ) to 275 injection. We have previously demonstrated that GLT-1 276 immunoreactivity is altered and GFAP immunoreactivity is 277 increased in the hippocampi following a higher dose kainic 278 acid injection of 74 nL (Hubbard et al., 2016) . For this study, 279 we selected a lower dose kainic acid injection volume of 280 64 nL to decrease mortality. Characteristics of hippocampal 281 sclerosis including dentate granule cell dispersion, neuronal 282 loss in CA1, and gliosis were observed, and are all hallmark 283 features of temporal lobe epilepsy (TLE) (Thom, 2014) .
284
A one-way ANOVA on GLT-1 immunoreactivity in the ipsi-285 lateral total hippocampus post-IHKA revealed a main effect 286 of time point (F(4,12) = 38.96, P < .0001) (Fig. 3) . Post hoc 287 Bonferroni tests revealed a significant increase in GLT-1 288 immunoreactivity at 1 (P < .0001) and 3 days post-IHKA 289 (P < .0001), followed by a downregulation at 7 days post-290 IHKA (P = .0223), and this returned to near baseline levels 291 by 30 days post-IHKA in the ipsilateral hippocampus 292 (P > .05) compared to saline controls (Fig. 3) . To determine transporter-1 (GLT-1) 348 We isolated synaptosomes to ensure collection of all three 349 elements of the tripartite synapse: pre-synaptic terminals,
350 post-synaptic elements, and perisynaptic astrocyte pro-351 cesses. Success of synaptosomal fractionation was con-352 firmed by probing for synaptosomal markers (Fig. 1B) (Fig. 1B) .
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We have previously dis- IHKA in the ipsilateral hippocampus (P = .0023) (Fig. 6C) . Fig. 2 . Glutamate transporter-1 (GLT-1) and glial fibrillary acidic protein (GFAP) immunoreactivity in the ipsilateral dorsal hippocampus after kainic acid-induced status epilepticus. 5X images of GLT-1 (green), GFAP (red), and DAPI (blue) immunoreactivity in the ipsilateral dorsal hippocampus after saline injections (control) and 1, 3, 7 and 30 days post-SE. SO = stratum oriens; SP = stratum pyramidale; SR = stratum radiatum; SLM = stratum lacunosum moleculare; ML = molecular layer; GCL = granule cell layer; H = hilus. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) 8.551, P = .0017), hilus (F Fig. 3 . Quantification of glutamate transporter-1 (GLT-1) immunoreactivity in the ipsilateral dorsal hippocampus. Mean gray scale values shown at the indicated time points after kainic acid-induced status epilepticus. For each time point post-IHKA, n = 3 animals were used. For saline injections (controls), n = 5 animals were used. * indicates P < .05, ** indicates P < .01, *** indicates P < .001 and **** indicates P < .0001 when compared to saline-injected animals (control). Fig. 4 . Glutamate transporter-1 (GLT-1) and glial fibrillary acidic protein (GFAP) immunoreactivity in the contralateral dorsal hippocampus after kainic acid-induced status epilepticus. 5X images of GLT-1 (green), GFAP (red), and DAPI (blue) immunoreactivity in the contralateral dorsal hippocampus after saline injections (control) and 1, 3, 7 and 30 days post-SE. SO = stratum oriens; SP = stratum pyramidale; SR = stratum radiatum; SLM = stratum lacunosum moleculare; ML = molecular layer; GCL = granule cell layer; H = hilus. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) 
464 (4,12) = 18.43, P < .0001) and lower blade (F(4,12) = 465 29.56, P < .0001) of the dentate gyrus, S. lucidum (F 466 (4,12) = 7.025, P = .0037), and S. pyramidale of CA3 (F 467 (4,12) = 8.697, P = .0016). Post hoc Bonferroni tests 468 revealed at 1 day post-IHKA, GLAST immunoreactivity 469 was significantly increased in S. pyramidale of CA1 (P =
470
.0040), S. radiatum (P < .0001), SLM (P = .0001), molecu-471 lar layer (P < .0001), the upper blade (P = .0019) and lower 472 blade (P < .0001) of the dentate gyrus, S. lucidum (P =
473
.0203), and S. pyramidale of CA3 (P = .0034). At 3 days Fig. 5 . Quantification of glutamate transporter-1 (GLT-1) immunoreactivity in the contralateral dorsal hippocampus. Mean gray scale values shown at the indicated time points after kainic acid-induced status epilepticus. For each time point post-IHKA, n = 3 animals were used. For saline injections (controls), n = 5 animals were used. * indicates P < .05 and ** indicates P < .01 when compared to saline-injected animals (control). (Fig. 10) . genesis. First, we found a significant upregulation in GLT- Fig. 7 . Glutamate aspartate transporter (GLAST) and glial fibrillary acidic protein (GFAP) immunoreactivity in the ipsilateral dorsal hippocampus after kainic acid-induced status epilepticus. 5 × images of GLAST (green), GFAP (red), and DAPI (blue) immunoreactivity in the ipsilateral dorsal hippocampus after saline injections (control) and 1, 3, 7 and 30 days post-SE. SO = stratum oriens; SP = stratum pyramidale; SR = stratum radiatum; SLM = stratum lacunosum moleculare; ML = molecular layer; GCL = granule cell layer; H = hilus. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
533 1 immunoreactivity at 1 and 3 days post-IHKA in the dorsal 534 hippocampus. Second, we found that GLT-1 immunoreac-535 tivity is significantly downregulated at 7 days post-IHKA in 536 the ipsilateral hippocampus. Third, we found that synapto-537 somal GLT-1 protein levels were significantly downregu-538 lated 7 days post-IHKA in the ipsilateral hippocampus. 539 Fourth, GLAST immunoreactivity was significantly 540 increased at 1 day and 3 days post-IHKA in a layer-541 specific manner in the ipsilateral hippocampus. While the 542 current study does not establish causation or mechanism, 543 these results further support the hypothesis that astrocytic 544 glutamate transporter dysregulation may contribute to the 545 development of epilepsy.
546 Changes in glutamate transporter-1 (GLT-1) regional 547 and cellular expression following SE 548 Numerous studies have established that there is an 549 increase in extracellular glutamate levels during seizures 550 (During and Spencer, 1993; Hubbard et al., 2013; Medina-551 Ceja et al., 2015; Soukupova et al., 2015) . Increased levels 552 of extracellular glutamate are likely due to excess glutamate 553 release or reduced glutamate reuptake. GLT-1 is responsi-554 ble for over 90% of the total glutamate clearance in the 555 CNS (Danbolt, 2001) . Therefore, changes in GLT-1 expres-556 sion can greatly impact synaptic activity and function. Mice 557 that globally lack GLT-1 develop lethal spontaneous epilep-558 tic seizures resulting in death early postnatally (Tanaka 559 et al., 1997). Interestingly, mice that regionally lack GLT-1 560 only in the dorsal forebrain survive to adulthood but display 561 transient focal seizures distinct from the generalized sei-562 zures observed in global GLT-1 knockout mice (Sugimoto 563 et al., 2018) . This study showed that regional loss of GLT-564 1 is sufficient to induce spontaneous seizures. Our current 565 study is the first to examine changes in synaptosomal 566 GLT-1 expression at both early and chronic time points dur-567 ing epileptogenesis. Our data are the first to address the 568 subcellular pool of GLT-1 available for use at astrocytic peri-569 synaptic processes, the functional site of glutamate uptake 570 at glutamatergic synapses. Future studies will need to 571 address the exact timing of onset of spontaneous seizures 572 compared to timing of GLT-1 downregulation, and to deter-573 mine whether manipulation of GLT-1 levels will inhibit 574 epileptogenesis.
575
Excess extracellular glutamate has been shown to pro-576 duce excitotoxicity in other neurological diseases including 577 Alzheimer's disease (AD) and amyotrophic lateral sclerosis 578 (ALS) (Foran and Trotti, 2009; Danysz and Parsons, 579 2012) . GLT-1 expression and subcellular localization has 580 also been shown to be altered in neurological diseases 581 (Lin et al., 1998; Jacob et al., 2007; Foran et al., 2014; 582 Munoz-Ballester et al., 2016; Zhang et al., 2017) . Under nor-583 mal physiological conditions, GLT-1 tends to cluster at 584 astrocytic processes and endfeet and is localized at the 585 plasma membrane (Schreiner et al., 2014) . Recent studies 586 have shown that GLT-1 dysfunction and changes in locali-587 zation could be regulated at the post-translational level in 588 many of these diseases (Huang et , n = 5 animals were used. * indicates P < .05, ** indicates P < .01, *** indicates P < .001 and **** indicates P < .0001 when compared to saline-injected animals (control). . Glutamate aspartate transporter (GLAST) and glial fibrillary protein (GFAP) immunoreactivity in the contralateral dorsal hippocampus after kainic acid-induced status epilepticus. 5 × images of GLAST (green), GFAP (red), and DAPI (blue) immunoreactivity in the contralateral dorsal hippocampus after saline injections (control) and 1, 3, 7 and 30 days post-SE. SO = stratum oriens; SP = stratum pyramidale; SR = stratum radiatum; SLM = stratum lacunosum moleculare; ML = molecular layer; GCL = granule cell layer; H = hilus. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
In summary, we demonstrate marked changes in astrocy-701 tic glutamate transporters, GLT-1 and GLAST, during epi-702 leptogenesis in the IHKA model of epilepsy. We showed 703 that GLT-1 and GLAST immunoreactivity is increased in 704 the hippocampus early after status epilepticus (1 and 705 3 days post-IHKA), but there is downregulation of 
